F. Hoffmann-La Roche Ltd: Roche to present new pivotal data

Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of

Related Keywords

United States , American , Nathalie Meetz , Polatuzumab Vedotin , Levi Garraway , Mabthera Rituxan , Gazyva Gazyvaro , Sileia Urech , Glofitamab Glofit , Venclexta Venclyxto , Karsten Kleine , Rocheand Linkedinand , Polatuzumab Vedotin Pola , Venetoclax Rituximab Ven , American Society Of Hematology , Subcutaneous Sc Administration Of Mosunetuzumab , Lymphoma Study Association , Head Of Global Product Development , Lymphoma Academic Research Organisation , American Society , Annual Meeting , Chief Medical Officer , Global Product , Live Media Event , Roche Haematology Newsroom , Versus Rituximab , Previously Untreated Diffuse Largeb Cell , Well Tolerated Treatment Option , Follicular Lymphoma , Who Have Received , Pivotal Results , Plus Polatuzumab Vedotin Has Promising Efficacy , Favorable Safety Profile , Refractory Aggressiveb Cell Non Hodgkin Lymphoma , Updated Results , Lenalidomide Has , Manageable Safety Profile , Encouraging Activity , Refractory Follicular Lymphoma , Initial Results , Refractoryb Cell Non Hodgkin Lymphomas , Step Up Dosing Induces High Response Rates , With Relapsed , Mantle Cell Lymphoma , Whom Had Failed Prior Bruton , Tyrosine Kinase Inhibitor , Data Support Manageable Safety , Encouraging Efficacy , Diffuse Largeb Cell Lymphoma , Obinutuzumab Induces High Complete Response Rates , Multiple Relapsed , Hodgkin Lymphoma , Non Hodgkin Lymphoma , Previously Untreated , Preliminary Results From , Show Clinically Meaningful Activity , Manageable Safety , Heavily Pre Treated , Refractory Multiple Myeloma , Short Duration Infusion Is Preferred , Healthcare Providers , Has Minimal Impact , Patient Reported Symptoms Among Patients , Advanced Follicular , Responses Are Observed , Mutational Spectrum , Venetoclax Plus , Poor Risk Cytogenetics , Venetoclax Combined , Lymphocytic Leukemia , Minimal Residual Disease , Randomized Phase , Moderate Hemophilia , Interim Analysis , Emicizumab Prophylaxis , Thrombotic Events , Patients With Paroxysmal Nocturnal Hemoglobinuria , Current Anti Complement , Trial Evaluating , Acute Uncomplicated Vaso Occlusive Episodes , Sickle Cell Disease , Placebo Controlled Phase , Crovalimab As Adjunct Treatment , Vaso Occlusive Episodes , World Health Organization Model Lists , Essential Medicines , Dow Jones Sustainability , Hoffmann , Oche , Present , Pivotal , Data , 021 , Rom , Road , Comprehensive , Portfolio , Challenging , Treatment , Standards , People , Flood , Disorders ,